Filtered By:
Drug: Humira
Vaccination: Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 239 results found since Jan 2013.
Physiologically based pharmacokinetic modelling of anti-tumour necrosis factor for IBD patients to predict the withdrawal time in pregnancy and vaccine time in infants
This study aimed to determine the optimal timing for the last dosing of anti-TNF agents (infliximab, adalimumab, and golimumab) in pregnant women with IBD, as well as to investigate the recommended vaccine schedules for infants exposed to these drugs. A physiologically based pharmacokinetic (PBPK) model of anti-TNF agents was built for adults and extrapolated to pregnant patients, foetuses, and infants. The PBPK models successfully predicted and verified the pharmacokinetics of infliximab, adalimumab, and golimumab in pregnancy, foetuses, and infants. The predicted pharmacokinetic data were within two-fold of the observed ...
Source: Clinical Pharmacology and Therapeutics - August 24, 2023 Category: Drugs & Pharmacology Authors: Jiarui Chen Rongfang Lin Guimu Guo Wanhong Wu Meng Ke Chengjie Ke Pinfang Huang Cuihong Lin Source Type: research
Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination
CONCLUSION: Anti-SARS-CoV-2 vaccination is considerably efficacious in IBD patients, with mRNA vaccines promoting better antibody levels. The negative impact of combined biological treatment, especially with high adalimumab drug levels, on serological response to vaccination should be considered. Although midterm durability of vaccination is encouraging, more data are needed to expand the existing understanding on this issue.PMID:37461738 | PMC:PMC10350576 | DOI:10.1177/17562848231183529
Source: Adv Data - July 18, 2023 Category: Epidemiology Authors: Tam ás Resál P éter Bacsur Mikl ós Horváth Kata Sz ántó Mariann Rutka Anita B álint Anna F ábián Ren áta Bor Zolt án Szepes J ános Fekete Klaudia Farkas P ál Miheller Tam ás Molnár Source Type: research
TREMFYA ® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis
SPRING HOUSE, PENNSYLVANIA, March 17, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA® (guselkumab) was associated with greater treatment persistencea compared to secukinumab or ixekizumab in bio-naïve and bio-experienced patientsb living with moderate to severe plaque psoriasis (PsO), based on pairwise analysesc of real-world data.[1],[2] Additionally, in a post-hoc analysis of Phase 3 VOYAGE 2 clinical trial results, TREMFYA demonstrated durable clinical efficacy, itch relief and quality-of-life improvements in patients living with scal...
Source: Johnson and Johnson - March 17, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
TREMFYA ®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study
Beerse, Belgium, 8 September 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for TREMFYA®▼(guselkumab) from the ongoing Phase 3b GUIDE study, which is designed to understand the impact of early intervention and potential dosing interval flexibility on the long-term disease course in adult patients with moderate to severe plaque psoriasis (Pso). These new data demonstrated that “super responders”a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score <3) at a rate that was non-inferior to ...
Source: Johnson and Johnson - September 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab
Reumatismo. 2022 May 3;74(1). doi: 10.4081/reumatismo.2022.1474.ABSTRACTNot available.PMID:35506319 | DOI:10.4081/reumatismo.2022.1474
Source: Reumatismo - May 4, 2022 Category: Rheumatology Authors: J Finsterer Source Type: research
Reply to: "Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab" by Josef Finsterer
Reumatismo. 2022 May 3;74(1). doi: 10.4081/reumatismo.2022.1482.ABSTRACTNot available.PMID:35506316 | DOI:10.4081/reumatismo.2022.1482
Source: Reumatismo - May 4, 2022 Category: Rheumatology Authors: B Maranini G Ciancio R Cultrera M Govoni Source Type: research
Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab
Reumatismo. 2022 May 3;74(1). doi: 10.4081/reumatismo.2022.1474.ABSTRACTNot available.PMID:35506319 | DOI:10.4081/reumatismo.2022.1474
Source: Herpes - May 4, 2022 Category: Infectious Diseases Authors: J Finsterer Source Type: research
Reply to: "Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab" by Josef Finsterer
Reumatismo. 2022 May 3;74(1). doi: 10.4081/reumatismo.2022.1482.ABSTRACTNot available.PMID:35506316 | DOI:10.4081/reumatismo.2022.1482
Source: Herpes - May 4, 2022 Category: Infectious Diseases Authors: B Maranini G Ciancio R Cultrera M Govoni Source Type: research
Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab
Reumatismo. 2022 May 3;74(1). doi: 10.4081/reumatismo.2022.1474.ABSTRACTNot available.PMID:35506319 | DOI:10.4081/reumatismo.2022.1474
Source: Herpes - May 4, 2022 Category: Infectious Diseases Authors: J Finsterer Source Type: research
Reply to: "Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab" by Josef Finsterer
Reumatismo. 2022 May 3;74(1). doi: 10.4081/reumatismo.2022.1482.ABSTRACTNot available.PMID:35506316 | DOI:10.4081/reumatismo.2022.1482
Source: Herpes - May 4, 2022 Category: Infectious Diseases Authors: B Maranini G Ciancio R Cultrera M Govoni Source Type: research
Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab
Reumatismo. 2022 May 3;74(1). doi: 10.4081/reumatismo.2022.1474.ABSTRACTNot available.PMID:35506319 | DOI:10.4081/reumatismo.2022.1474
Source: Reumatismo - May 4, 2022 Category: Rheumatology Authors: J Finsterer Source Type: research
Reply to: "Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab" by Josef Finsterer
Reumatismo. 2022 May 3;74(1). doi: 10.4081/reumatismo.2022.1482.ABSTRACTNot available.PMID:35506316 | DOI:10.4081/reumatismo.2022.1482
Source: Reumatismo - May 4, 2022 Category: Rheumatology Authors: B Maranini G Ciancio R Cultrera M Govoni Source Type: research
Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab
Reumatismo. 2022 May 3;74(1). doi: 10.4081/reumatismo.2022.1474.ABSTRACTNot available.PMID:35506319 | DOI:10.4081/reumatismo.2022.1474
Source: Reumatismo - May 4, 2022 Category: Rheumatology Authors: J Finsterer Source Type: research
Reply to: "Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab" by Josef Finsterer
Reumatismo. 2022 May 3;74(1). doi: 10.4081/reumatismo.2022.1482.ABSTRACTNot available.PMID:35506316 | DOI:10.4081/reumatismo.2022.1482
Source: Reumatismo - May 4, 2022 Category: Rheumatology Authors: B Maranini G Ciancio R Cultrera M Govoni Source Type: research
